Axsome Company Profile
✉ Email this page to a colleague
What is the competitive landscape for AXSOME
AXSOME has three approved drugs.
There are two hundred and eighty-one US patents protecting AXSOME drugs.
There are five hundred and fifty-five patent family members on AXSOME drugs in thirty-nine countries and thirty-one supplementary protection certificates in fifteen countries.
Summary for Axsome
| International Patents: | 555 |
| US Patents: | 281 |
| Tradenames: | 3 |
| Ingredients: | 3 |
| NDAs: | 3 |
| Patent Litigation for Axsome: | See patent lawsuits for Axsome |
Drugs and US Patents for Axsome
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Axsome | SYMBRAVO | meloxicam; rizatriptan benzoate | TABLET;ORAL | 215431-001 | Jan 30, 2025 | RX | Yes | Yes | 10,653,777 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Axsome Malta | SUNOSI | solriamfetol hydrochloride | TABLET;ORAL | 211230-001 | Jun 17, 2019 | AB | RX | Yes | No | 11,160,779 | ⤷ Start Trial | ⤷ Start Trial | |||
| Axsome | SYMBRAVO | meloxicam; rizatriptan benzoate | TABLET;ORAL | 215431-001 | Jan 30, 2025 | RX | Yes | Yes | 11,433,078 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Axsome
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Axsome Malta | SUNOSI | solriamfetol hydrochloride | TABLET;ORAL | 211230-001 | Jun 17, 2019 | 10,351,517 | ⤷ Start Trial |
| Axsome Malta | SUNOSI | solriamfetol hydrochloride | TABLET;ORAL | 211230-002 | Jun 17, 2019 | 11,753,368 | ⤷ Start Trial |
| Axsome Malta | SUNOSI | solriamfetol hydrochloride | TABLET;ORAL | 211230-001 | Jun 17, 2019 | 12,209,059 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Axsome Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 102253986 | ⤷ Start Trial |
| Australia | 2022204521 | ⤷ Start Trial |
| South Korea | 20220161414 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Axsome Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2316456 | 132017000142109 | Italy | ⤷ Start Trial | PRODUCT NAME: NALTREXONE/BUPROPIONE(MYSIMBA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/988, 20150330 |
| 1890684 | C01890684/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: SOLRIAMFETOLUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68177 22.03.2022 |
| 1890684 | 132020000000040 | Italy | ⤷ Start Trial | PRODUCT NAME: SOLRIAMFETOL O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, PREFERIBILMENTE UN SUO SALE CLORIDRATO(SUNOSI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1408, 20200120 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
